Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...
C. Hoyek, C. Eslinger, Angelo Pirozzi et al.· BMC Cancer· 0 citations
ABSTRACT Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as...
Joanna Kreidi, C. Hoyek, C. Eslinger et al.· Expert Opinion on Biological...· 0 citations
Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.
Nguyen H. Tran, M. Palmer, Angela Ulrich et al.· The Oncologist· 0 citations
Evaluating and monitoring reasoning fidelity should be a prerequisite for safe deployment of LLMs in oncology decision support, as endpoint accuracy alone may mask clinically meaningful reasoning failures.
Matthew Kenaston, U. Ayub, Mihir Parmar et al.· npj Digital Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
